SCHEMBL3287757

SCHEMBL3287757

O=[N+]([O-])c1cccc2nc(N3CCOCC3)sc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.53
NPC1 O15118 4/20 0.53
RAB9A P51151 4/20 0.53
CYP1A2 P05177 1/20 0.50
CYP2C9 P11712 1/20 0.50
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
POLB P06746 2/20 0.48
MAPT P10636 5/20 0.46
GAA P10253 1/20 0.46
ALOX15 P16050 1/20 0.45
CTSB P07858 1/20 0.44
ACP1 P24666 1/20 0.44
AR P10275 1/20 0.43
ALOX5 P09917 1/20 0.42
PTGS2 P35354 1/20 0.42
PKM P14618 1/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPK1 P28482 2/20 0.42
APOBEC3A P31941 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8050601 0.78 SMN1; SMN2 (0.61) SMN1; SMN2NPC1RAB9APOLBMAPT
SCHEMBL3284981 0.77 SMN1; SMN2 (0.60) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL8057526 0.75 SMN1; SMN2 (0.57) SMN1; SMN2NPC1RAB9ACYP1A2MAPT
SCHEMBL9762583 0.74 ALDH1A1 (0.54) SMN1; SMN2NPC1RAB9ACYP1A2CYP2C9
SCHEMBL14824416 0.73 MAPT (0.55) SMN1; SMN2NPC1RAB9ACYP1A2CYP2C9
SCHEMBL3293261 0.73 MEN1 (0.58) SMN1; SMN2NPC1RAB9ACYP1A2MEN1
SCHEMBL14809676 0.72 RAB9A (0.54) SMN1; SMN2NPC1RAB9ACYP1A2CYP2C9
SCHEMBL14824501 0.72 RAB9A (0.79) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL312049 0.72 TP53 (0.53) CYP1A2CYP2C9MEN1KMT2APOLB
SCHEMBL3287046 0.71 MEN1 (0.60) SMN1; SMN2NPC1RAB9ACYP1A2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7714009-B2 Nitrogen-containing fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-11 US disclosed
EP-1677791-A4 NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2007-08-15 EP disclosed
US-20070135452-A1 Nitrogen-containing fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-06-14 US disclosed
EP-1677791-A2 NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2006-07-12 EP disclosed
WO-2005044793-A2 NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135452-A1 Nitrogen-containing fused heterocyclic compounds NPY4R, NR4A3, NR3C2 SMN1; SMN2 2597/4885NPC1 2729/4885RAB9A 2477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.